CXCR4 and renal cell carcinoma: Targeting the CXCR4-CXCL12 axis could revert the tolerogenic polarization of the microenvironment rich of immunosuppressive cells such as Tregs cells M2 and N2 neutrophils [25, 30, 26], improving immunotherapeutic intervention in patient with RCC.